Natural medicine HLXL targets multiple pathways of amyloid-mediated neuroinflammation and immune response in treating alzheimer's disease

Publication type:
Journal article
Metadata:
Autoren
  • Yingxia Liang
  • David YW Lee
  • Sherri Zhen
  • Haoqi Sun
  • Biyue Zhu
  • Jing Liu
  • Dan Lei
  • Chih-Chung Jerry Lin
  • Siyi Zhang
  • Nicholas A Jacques
  • Luisa Quinti
  • Chongzhao Ran
  • Changning Wang
  • Ana Griciuc
  • Se Hoon Choi
  • Rong Hua Dai
  • Thomas Efferth
  • Rudolph E Tanzi
  • Can Zhang
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000822932800001&DestLinkType=FullRecord&DestApp=WOS_CPL
DOI
10.1016/j.phymed.2022.154158
eISSN
1618-095X
Externe Identifier
  • Clarivate Analytics Document Solution ID: 2U1OS
  • PubMed Identifier: 35728383
ISSN
0944-7113
Zeitschrift
PHYTOMEDICINE
Schlüsselwörter
  • Alzheimer?s disease
  • Natural medicine
  • HlXL
  • Neuroinflammation
  • Innate immune response
Artikelnummer
ARTN 154158
Datum der Veröffentlichung
2022
Status
Published
Titel
Natural medicine HLXL targets multiple pathways of amyloid-mediated neuroinflammation and immune response in treating alzheimer's disease
Sub types
  • Article
Ausgabe der Zeitschrift
104

Data source: Web of Science (Lite)

Other metadata sources:
Autoren
  • Yingxia Liang
  • David YW Lee
  • Sherri Zhen
  • Haoqi Sun
  • Biyue Zhu
  • Jing Liu
  • Dan Lei
  • Chih-Chung Jerry Lin
  • Siyi Zhang
  • Nicholas A Jacques
  • Luisa Quinti
  • Chongzhao Ran
  • Changning Wang
  • Ana Griciuc
  • Se Hoon Choi
  • Rong Hua Dai
  • Thomas Efferth
  • Rudolph E Tanzi
  • Can Zhang
DOI
10.1016/j.phymed.2022.154158
ISSN
0944-7113
Zeitschrift
Phytomedicine
Sprache
en
Artikelnummer
154158
Paginierung
154158 - 154158
Datum der Veröffentlichung
2022
Status
Published
Herausgeber
Elsevier BV
Herausgeber URL
http://dx.doi.org/10.1016/j.phymed.2022.154158
Datum der Datenerfassung
2024
Titel
Natural medicine HLXL targets multiple pathways of amyloid-mediated neuroinflammation and immune response in treating alzheimer's disease
Ausgabe der Zeitschrift
104

Data source: Crossref

Abstract
<h4>Background</h4>Based on the complex pathology of AD, a single chemical approach may not be sufficient to deal simultaneously with multiple pathways of amyloid-tau neuroinflammation. A polydrug approach which contains multiple bioactive components targeting multiple pathways in AD would be more appropriate. Here we focused on a Chinese medicine (HLXL), which contains 56 bioactive natural products identified in 11 medicinal plants and displays potent anti-inflammatory and immuno-modulatory activity.<h4>Hypothesis/purpose</h4>We investigated the neuroimmune and neuroinflammation mechanisms by which HLXL may attenuate AD neuropathology. Specifically, we investigated the effects of HLXL on the neuropathology of AD using both transgenic mouse models as well as microglial cell-based models.<h4>Study design</h4>The 5XFAD transgenic animals and microglial cell models were respectively treated with HLXL and Aβ42, and/or lipopolysaccharide (LPS), and then analyzed focusing on microglia mediated Aβ uptake and clearance, as well as pathway changes.<h4>Methods</h4>We showed that HLXL significantly reduced amyloid neuropathology by upregulation of microglia-mediated phagocytosis of Aβ both in vivo and in vitro. HLXL displayed multi-modal mechanisms regulating pathways of phagocytosis and energy metabolism.<h4>Results</h4>Our results may not only open a new avenue to support pharmacologic modulation of neuroinflammation and the neuroimmune system for AD intervention, but also identify HLXL as a promising natural medicine for AD.<h4>Conclusion</h4>It is conceivable that the traditional wisdom of natural medicine in combination with modern science and technology would be the best strategy in developing effective therapeutics for AD.
Addresses
  • Genetics and Aging Research Unit, McCance Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA; Department of Anesthesiology, Weifang Medical University, Weifang, Shandong, China.
Autoren
  • Yingxia Liang
  • David YW Lee
  • Sherri Zhen
  • Haoqi Sun
  • Biyue Zhu
  • Jing Liu
  • Dan Lei
  • Chih-Chung Jerry Lin
  • Siyi Zhang
  • Nicholas A Jacques
  • Luisa Quinti
  • Chongzhao Ran
  • Changning Wang
  • Ana Griciuc
  • Se Hoon Choi
  • Rong Hua Dai
  • Thomas Efferth
  • Rudolph E Tanzi
  • Can Zhang
DOI
10.1016/j.phymed.2022.154158
eISSN
1618-095X
Externe Identifier
  • PubMed Identifier: 35728383
Funding acknowledgements
  • Cure Alzheimer&apos;s Fund:
Open access
false
ISSN
0944-7113
Zeitschrift
Phytomedicine : international journal of phytotherapy and phytopharmacology
Schlüsselwörter
  • Microglia
  • Animals
  • Mice, Transgenic
  • Mice
  • Alzheimer Disease
  • Amyloidosis
  • Disease Models, Animal
  • Phagocytosis
  • Amyloid beta-Peptides
  • Neuroinflammatory Diseases
Sprache
eng
Medium
Print-Electronic
Online publication date
2022
Paginierung
154158
Datum der Veröffentlichung
2022
Status
Published
Datum der Datenerfassung
2022
Titel
Natural medicine HLXL targets multiple pathways of amyloid-mediated neuroinflammation and immune response in treating alzheimer's disease.
Sub types
  • Journal Article
Ausgabe der Zeitschrift
104

Data source: Europe PubMed Central

Abstract
BACKGROUND: Based on the complex pathology of AD, a single chemical approach may not be sufficient to deal simultaneously with multiple pathways of amyloid-tau neuroinflammation. A polydrug approach which contains multiple bioactive components targeting multiple pathways in AD would be more appropriate. Here we focused on a Chinese medicine (HLXL), which contains 56 bioactive natural products identified in 11 medicinal plants and displays potent anti-inflammatory and immuno-modulatory activity. HYPOTHESIS/PURPOSE: We investigated the neuroimmune and neuroinflammation mechanisms by which HLXL may attenuate AD neuropathology. Specifically, we investigated the effects of HLXL on the neuropathology of AD using both transgenic mouse models as well as microglial cell-based models. STUDY DESIGN: The 5XFAD transgenic animals and microglial cell models were respectively treated with HLXL and Aβ42, and/or lipopolysaccharide (LPS), and then analyzed focusing on microglia mediated Aβ uptake and clearance, as well as pathway changes. METHODS: We showed that HLXL significantly reduced amyloid neuropathology by upregulation of microglia-mediated phagocytosis of Aβ both in vivo and in vitro. HLXL displayed multi-modal mechanisms regulating pathways of phagocytosis and energy metabolism. RESULTS: Our results may not only open a new avenue to support pharmacologic modulation of neuroinflammation and the neuroimmune system for AD intervention, but also identify HLXL as a promising natural medicine for AD. CONCLUSION: It is conceivable that the traditional wisdom of natural medicine in combination with modern science and technology would be the best strategy in developing effective therapeutics for AD.
Date of acceptance
2022
Autoren
  • Yingxia Liang
  • David YW Lee
  • Sherri Zhen
  • Haoqi Sun
  • Biyue Zhu
  • Jing Liu
  • Dan Lei
  • Chih-Chung Jerry Lin
  • Siyi Zhang
  • Nicholas A Jacques
  • Luisa Quinti
  • Chongzhao Ran
  • Changning Wang
  • Ana Griciuc
  • Se Hoon Choi
  • Rong Hua Dai
  • Thomas Efferth
  • Rudolph E Tanzi
  • Can Zhang
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/35728383
DOI
10.1016/j.phymed.2022.154158
eISSN
1618-095X
Zeitschrift
Phytomedicine
Schlüsselwörter
  • Alzheimer's disease
  • HlXL
  • Innate immune response
  • Natural medicine
  • Neuroinflammation
  • Alzheimer Disease
  • Amyloid beta-Peptides
  • Amyloidosis
  • Animals
  • Disease Models, Animal
  • Mice
  • Mice, Transgenic
  • Microglia
  • Neuroinflammatory Diseases
  • Phagocytosis
Sprache
eng
Country
Germany
Paginierung
154158
PII
S0944-7113(22)00236-7
Datum der Veröffentlichung
2022
Status
Published
Datum, an dem der Datensatz öffentlich gemacht wurde
2022
Titel
Natural medicine HLXL targets multiple pathways of amyloid-mediated neuroinflammation and immune response in treating alzheimer's disease.
Sub types
  • Journal Article
Ausgabe der Zeitschrift
104

Data source: PubMed

Beziehungen:
Property of

Tools